Scarica l'app Stockscreener
5.412
2.34%
-0.128
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
Earnings Recap: Is Aldeyra Therapeutics Inc exposed to political riskQuarterly Risk Review & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Market Review: Does Aldeyra Therapeutics Inc have consistent dividend growthJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Will BOOT benefit from green energy policies2025 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
How volatile is Aldeyra Therapeutics Inc. stockJuly 2025 Selloffs & Risk Adjusted Buy and Sell Alerts - mfd.ru
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewir - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Thera - The National Law Review
Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners - simplywall.st
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update - MarketBeat
Behavioral Patterns of ALDX and Institutional Flows - Stock Traders Daily
FDA Extends Review Timeline for Aldeyra's Dry Eye Drug Candidate () - aktiencheck.de
Support Test: Does Aldeyra Therapeutics Inc have a sustainable dividend2025 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aldeyra Therapeutics (ALDX) Leads in Earnings Momentum - GuruFocus
Analysis Recap: Is Aldeyra Therapeutics Inc stock trending bullish2025 Momentum Check & Community Trade Idea Sharing Platform - baoquankhu1.vn
Insider Buy: Does National Energy Services Reunited Corp Equity Warrant stock reflect fundamentals2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
Trend Review: Is Envirotech Vehicles Inc in accumulation or distribution phaseJobs Report & Consistent Profit Trade Alerts - baoquankhu1.vn
Will Betterware de Mxico SAPI de CV benefit from green energy policiesMarket Movers & Real-Time Stock Entry Alerts - baoquankhu1.vn
Sell Signal: What is the dividend yield of Trailblazer Merger Corporation I Equity RightJuly 2025 Update & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Aldeyra drops as FDA delays review of marketing application for lead drug - MSN
Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Weekly Profit Report & Risk Controlled Daily Trade Plans - Улправда
Market Trends: Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Portfolio Risk Report & Fast Gain Stock Tips - Bộ Nội Vụ
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
Can Aldeyra Therapeutics Inc. stock rebound after recent weaknessDay Trade & Daily Entry Point Trade Alerts - Улправда
Why Aldeyra Therapeutics Inc. stock attracts high net worth investors2025 Big Picture & Weekly Momentum Stock Picks - Улправда
Growth Value: Why Aldeyra Therapeutics Inc. stock attracts high net worth investorsEarnings Risk Summary & Detailed Earnings Play Strategies - Улправда
News | postregister.comAldeyra Therapeutics, Inc.Common Stock (Nasdaq:ALDX) Detailed Stock Data - FinancialContent
(ALDX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Aldeyra Therapeutics announces chief development officer resignation - MSN
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
What to keep an eye on in 2026 - Eyes On Eyecare
Aldeyra Therapeutics Chief Development Officer Stephen Machatha to Resign - marketscreener.com
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Aldeyra Therapeutics chief development officer to step down by March 2026 - Investing.com Nigeria
Aldeyra Therapeutics Announces Chief Development Officer Resignation - TipRanks
Aldeyra Therapeutics chief development officer to step down by March 2026 By Investing.com - Investing.com India
Aldeyra Therapeutics Announces Resignation of Chief Development Officer - TradingView — Track All Markets
Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha
Why is Aldeyra Therapeutics stock surging after FDA delayed its dry eye drug decision? - MSN
Why (ALDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) Institutional Shareholders Had a Great Week as One-year Returns Increased After a 24% Gain Last Week - 富途牛牛
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Can SAL Steel Limited Maintain Growth Without Diluting ShareholdersLong-Term Investment Plans & Small Investment Capital Gains - earlytimes.in
What dividend safety score for Aldeyra Therapeutics Inc. stockMarket Trend Summary & Reliable Trade Execution Plans - DonanımHaber
What Wall Street predicts for Aldeyra Therapeutics Inc. stock priceWeekly Stock Summary & Real-Time Market Sentiment Reports - Улправда
Will Aldeyra Therapeutics Inc. stock benefit from infrastructure spendingSwing Trade & Fast Gaining Stock Strategy Reports - Улправда
ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being InvestigatedContact the Firm if You Lost Money - 28/22 News
Aldeyra Therapeutics Earnings Notes - Trefis
Aldeyra Therapeutics Sees Unusually Large Options Volume (NASDAQ:ALDX) - Defense World
1.20%
3.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):